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Purpose: Our recent reports indicated that the molecular changes of pterygia are similar to tumor cells. We believe that
pterygia may have a similar mechanism in oncogenesis. Many studies have revealed that E-cadherin associated protein
expression decreases in many tumors and pterygia. E-cadherin may be a marker for both tumor metastasis and prognosis.
However, no studies have examined the reason for E-cadherin protein inactivation in pterygia. Therefore, this study aimed
to analyze the association of E-cadherin promoter hypermethylation with protein inactivation in pterygial tissues.
Methods: E-cadherin methylation-status and the expression of E-cadherin and β-catenin protein were studied using
methylation-specific  PCR  and  immunohistochemistry,  respectively,  on  120  pterygial  specimens  and  30  normal
conjunctivas.
Results: Hypermethylation of E-cadherin gene promoter was detected in 32 (26.7%) of the 120 pterygial specimens. A
total of 79 (65.8%) pterygial specimens tested positive for E-cadherin protein expression and 41 (34.2%) specimens tested
negative. The E-cadherin staining was limited to the membrane of the epithelial layer. There was a reverse correlation
between E-cadherin gene promoter hypermethylation and E-cadherin protein expression (p<0.0001). Aberrant localization
of β-catenin was higher in the E-cadherin negative group than in E-cadherin positive group.
Conclusions: Our study demonstrates E-cadherin gene promoter hypermethylation were associated with low or absent
expression of E-cadherin. Moreover, loss of E-cadherin protein may contribute to aberrant localization of β-catenin. These
data provide evidence that methylation exists in pterygia and may play a role in their development.
Pterygium  has  long  been  considered  a  degenerative
disease. However, following the finding that the p53 protein
is  abnormally  expressed  in  epithelium,  pterygium  is  now
considered  to  be  a  UV  exposure-related  uncontrolled  cell
proliferation that is similar to a tumor [1-7].
There  are  several  adhesion  molecules,  including
cadherin, cell-cell adhesion molecules (CAMs), selectin, and
integrin, which maintain tissue architecture [8]. E-cadherin
(120  kDa;  human  chromosome  16q),  a  transmembrane
protein, plays a role in organ morphogenesis, tissue formation,
and  proper  development  during  embryogenesis  [9].  The
extracellular domain of E-cadherin connects neighboring cells
with  adherent  junctions  through  calcium-dependent
homophilic  interactions  [9].  The  cytoplasmic  part  of  E-
cadherin links the cytoskeleton via α-catenin, β-catenin, and
p120ctm  [10].  β-catenin  not  only  contributes  to  cellular
adhesion but is also a central component in the Wingless/Wnt
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(Wg/Wnt)  signaling  cascade,  which  is  important  in  axis
determination and organogenesis during early development
[11,12]. Without a mitotic signal, free cytoplasmic β-catenin
would be degraded by the ubiquitin-proteasome system via
phosphorylation by the protein complex, which is composed
of  adenomatous  polyposis  coli  (APC)  tumor  suppresser
protein,  Axin,  and  serine  threonine  glycogen  synthetase
kinase (GSK-3β) [13]. This mechanism maintains a low level
of free cytoplasmic β-catenin. However, free cytoplasmic β-
catenin will increase with the appearance of mitotic signals
(Wnt  protein)  or  reduced  expression  of  E-cadherin.  The
binding of the Wnt protein to its cognate frizzled receptor
leads to activation of the dishevelled (Dsh) protein, which
down-regulates  the  APC-Axin-  GSK-3β  protein  complex
[14]. Hence, cytoplasmic β-catenin evades degradation and
accumulates in the cytoplasm [15,16]. In addition, reduced
expression of E-cadherin will lead to the decomposition of the
E-cadherin-catenin  complex  and  to  an  increase  in  free
cytoplasmic β-catenin. E-cadherin also mediates epithelial
cellular  adhesion.  When  the  free  cytoplasmic  β-catenin
increases, it eventually translocates into the nucleus and binds
with transcription factors LEF (Lymphoid Enhancer Factor)
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1047and TCF (T Cell Factor) resulting in the activation of target
genes [17,18]. The target genes, such as cyclin D1 and c-myc,
are  responsible  for  cell  proliferation  and  neoplastic
transformation [19,20]. Therefore, E-cadherin contributes to
epithelial differentiation.
Methylation of gene regulatory elements, a well known
epigenetic change, acts as an important alternative to genetic
alteration for gene inactivation. Aberrant methylation of the
promoter region of tumor suppressor genes and the associated
gene silencing plays an important role in the pathogenesis of
most, if not all types of human cancer [21]. The methylation
of  CpG  islands  in  the  promoter  region  silences  gene
expression and is a normal event that occurs in cells to regulate
gene  expression.  However,  the  mechanisms  involved  in
hypermethylated  DNA  loci  remain  unclear.  CpG  island
hypermethylation of the E-cadherin gene (CDH1) promoter is
a contributing factor in the inactivation of E-cadherin [22]. E-
cadherin  promoter  hypermethylation  is  involved  in  many
types of cancers [9].
In this study, we hypothesized that the E-cadherin gene
loses  function  in  pterygium.  We  also  hypothesized  that
besides gene mutations, there are epigenetic changes (e.g.,
hypermethylation of gene regulatory elements) in pterygium.
To test these hypotheses, we analyzed hypermethylation of
the  E-cadherin  gene  promoter  in  pterygium  and  the
relationship  between  hypermethylation  and  E-cadherin
protein expression. In addition, the association of E-cadherin
protein with localization of β-catenin was analyzed in this
study.
METHODS
Patients and controls: Pterygial samples were harvested from
120 patients undergoing pterygium surgery and the patients
were asked to submit a written informed consent approved by
the Institutional Review Board. Patients in whom the apex of
the pterygium had invaded the cornea by more than 1 mm were
included  in  this  study.  The  controls  included  normal
conjunctival samples collected from the superior conjunctiva
of  15  patients  and  the  medial  conjunctiva  of  15  patients
without  pterygium  and  pinguecula  who  were  undergoing
cataract or vitreoretinal surgery. There were 70 males and 50
females  in  the  pterygium  group  (age  range=52–78  years,
means=62.5 years), and there were 15 males and 15 females
in  the  control  group  (age  range=55–75  years,  mean=62.8
years).  Normal  conjunctival  samples  were  collected  from
bulbar  conjunctivas.  All  pterygial  specimens  came  from
primary pterygium.All specimens were fixed in formalin and
paraffin embedded.
Immunohistochemistry: All sections were deparaffinized in
xylene,  sequentially  rehydrated  in  alcohol  and  washed  in
phosphate-buffered saline. Sections used for E-cadherin and
β-catenin, detection were heated in a microwave oven twice
for 5 min in a citrate buffer (pH 6.0). Mouse anti- E-cadherin
and a β-catenin monoclonal antibody (at a dilution of 1:200)
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were used
as the primary antibodies. The sections were incubated with
the primary antibodies for 60 min at room temperature, and
the signals were detected by using a conventional streptavidin
peroxidase  method  (LSAB  kit  K675;  Dako,  Copenhagen,
Denmark). Signals
were developed with 3,3'-diaminobenzidine for 5 min and
counterstained with hematoxylin. The detailed protocol used
has been described in our previous reports [23]. Negative
controls that did not include the primary antibodies were set
up. Conjunctiva tissues and lung epithelial cells were used as
the positive control. The results were evaluated independently
by three observers and were scored for the percentage of
positive expression. In E-cadherin protein, which was only
expressed in the membrane, we counted the positive rate of
membrane expression of total epithelial cells in β-catenin,
which  were  expressed  in  the  membrane,  cytoplasm,  and
nuclei.  We  separated  the  expression  site  to  two  groups,
membrane  expression  and  cytoplasm/nuclei  expression.
Score 0, no positive staining; score +, from 1% to 10%; score
++, from 11% to 50%; and score +++, more than 50% positive
cells. In this study, scores of ++, and +++ were considered to
be  positive  immunostaining,  and  a  score  of  0  or  +  was
classified as negative immunostaining.
Methylation-specific PCR (MSP) and direct sequencing: For
bisulfite treatment, 2 μg of DNA was diluted in 50 μl water
and denatured in 0.2 M NaOH at 37 °C for 20 min. Sodium
bisulfite NaHSO3 (130 μl; 3.5 mol/l; freshly prepared; Sigma-
Aldrich, Inc., St. Louis, MO) and hydroquinone (10 μl; 30
mmol/l; freshly prepared; Sigma) were added to the samples
and incubated at 95 °C for 5 min and 50 °C for 16 h. After
bisulfate modified, DNA were purified using the Wizard DNA
Clean-Up System (Promega Corp., Madison, WI) according
to the manufacturer’s instructions. The purified DNA was
mixed with 0.6 N NaOH to a final concentration of 0.3 N,
incubated for 10 min at room temperature, and then ethanol
precipitated. The DNA was then re-suspended in 10–15 μl
ddH2O and stored at −20 °C until it was used for PCR. PCR
was performed using primers specific for the methylated E-
cadherin  sequence.  Sense  and  antisense  primers  for  the
methylated sequence were 5′-TGT AGT TAC GTA TTT ATT
TTT AGT GGC GTC-3′and 5′-CGA ATA CGA TCG AAT
CGA ACC G-3′, respectively. All bisulfate-treated DNA was
also amplified using primers specific to the unmethylated E-
cadherin  sequence.  Sense  and  antisense  primers  for  the
unmethylated sequence were 5′-TGG TTG TAG TTA TGT
ATT TGT TTT TAG TGG TGT T-3′ and 5′-ACA CCA AAT
ACA ATC AAA TCA AAC CAA A-3, respectively. The PCR
consisted of an initial denaturation step at 95 °C for 5 min
followed by 40 cycles at 94 °C for 60 s; 65 °C (for methylated
E-cadherin)/60 °C (for unmethylated E-cadherin) for 50 s;
72 °C for 50 s; and a final extension step at 72 °C for 10 min.
PCR products were analyzed by agarose gel electrophoresis
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modified  DNA  from  peripheral  blood  lymphocytes  of  a
healthy  individual  served  as  a  positive  control  for  the
unmethylated  alleles,  and  unconverted  DNA  from  normal
lymphocytes was used as a positive control for the methylated
alleles.
Statistical Analysis: Statistical analysis was performed using
the SPSS statistical software program (SPSS Inc., Chicago,
IL). The Fisher’s exact test was applied for statistical analysis.
A p<0.05 was considered to be statistically significant.
RESULTS
E-cadherin protein expression in pterygium: Immunostaining
scores of 0 and + were considered negative, and ++ and +++
were considered positive (cutoff level set at 10%). In the
pterygium group, the E-cadherin, proteins were detected in 79
(65.8%)  patients  (Table  1).  E-cadherin  was  positive  for
immunostaining in the membrane (Figure 1).
Loss  of  E-cadherin  protein  expression  in  pterygium  may
correlate  with  promoter  methylation:  To  understand  the
reason for negative expression of E-cadherin in pterygium,
MS-PCR  was  used  to  analyze  E-cadherin  promoter
hypermethylation. The relationship between E-cadherin gene
promoter  hypermethylation  and  E-cadherin  protein
expression is shown in Table 2. Of the 32 pterygium cases
with E-cadherin gene promoter hypermethylation, 21 (65.6%)
were negative for E-cadherin protein expression, which was
higher  than  the  pterygium  cases  without  E-cadherin  gene
promoter hypermethylation (22.7%). There was a significant
reverse  correlation  between  E-cadherin  gene  promoter
hypermethylation  and  E-cadherin  protein  expression
(p<0.0001; Table 2).
β-catenin  protein  expression  in  pterygium:  As  we  know,
reduced  expression  of  E-cadherin  will  lead  to  the
decomposition of the E-cadherin-catenin complex and to an
increase  in  free  cytoplasmic  β-catenin.  When  the  free
cytoplasmic β-catenin increases, it finally translocates into the
nucleus resulting in the activation of cyclin D1 and c-myc
which are responsible for cell proliferation and neoplastic
transformation [19,20]. We further analyzed the correlation
of E-cadherin and β-catenin protein expression in pterygium.
In the pterygium group, the β-catenin proteins were detected
in 58 (48.3%) patients (Table 1). Additionally, as shown in
Figure 1, the aberrant protein localization of β-catenin was
also detected in pterygium. In 58 β-catenin positive patients,
56.9% (33 of 58) were detected in the membrane and 43.1%
(25 of 58) were detected in cytoplasm or nuclei. In the normal
conjunctiva  group,  all  specimens  were  positive  for
immunostaining in the membrane.
Correlation of E-cadherin and β-catenin protein expression:
As we know, the extracellular domain of E-cadherin connects
neighboring cells with adherent junctions through calcium-
dependent homophilic interactions and the cytoplasmic part
of E-cadherin links the cytoskeleton via β-catenin [9]. To
understand the relationship between the E-cadherin signaling
pathway and associated protein expression, the correlations of
E-cadherin and β-catenin protein expression and localization
were analyzed (Table 3). As shown in Table 3, in the 41 cases
of E-cadherin negative expression, 43.9% (18 of 41) had β-
catenin negative expression, 7.4% (3 of 41) had β-catenin
membrane  expression,  and  48.7%  (20  of  41)  had  nuclei/
cytoplasm expression. Additionally, in the 79 cases of E-
cadherin positive expression, 55.7% (44 of 79) had β-catenin
negative  expression,  38.0%  (30  of  79)  had  β-catenin
membrane  expression,  and  6.3%  (5  of  79)  had  nuclei/
cytoplasm expression. The aberrant protein localization of β-
catenin in the E-cadherin negative group was significantly
higher than in the positive group (p<0.0001).
DISCUSSION
Pterygia, previously considered a degenerative process of the
corneal limbus, is characterized by the invasion of a fleshy
triangle of conjunctival tissue onto the cornea. Shimmura et
al. [24] demonstrated that increased activity of telomerase in
pterygia epithelial cells, indicating their hyperproliferative
nature. Satoru et al. [25] reported that increased expression of
Ki67, a cell proliferation marker, was noted in pterygia. We
assume that it is the proliferative capacities of pterygial cells
which make pterygia appear to have a similar mechanism to
tumorigenesis.
TABLE 1. E-CADHERIN AND β-CATENIN PROTEIN EXPRESSION IN PTERYGIUM ANALYZED BY IMMUNOHISTOCHEMISTRY.
  Pterygium Control
Protein N % N %
E-cadherin
Negative 41 34.2 0 0
Positive 79 65.8 30 100
β-catenin
Negative 62 51.7 0 0
Positive        
Membrane 33 27.5 30 100
Nuclei/Cytoplasm 25 20.8 0 0
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occurrence of contact inhibition of cell growth [9]. Altered
expression of E-cadherin may result in the loss of contact
inhibition  and  abnormal  cell  proliferation,  hence
Figure 1. Representative immunostaining results for E-cadherin associated protein expression. A: The first antibody replaced with IgG was
used as the negative control. B: The representative positive β-catenin immunostaining in conjunctival tissue was used as the positive control.
C: E-cadherin protein expression detected in the membrane (400×). D: β-Catenin protein expression detected in the membrane (400×). In
addition, aberrant localization of β-catenin was also detected in the cytoplasm/nuclei (E) and nucleus (F) (400×).
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1050tumorigenesis  takes  place  [26,27].  In  this  study,  reduced
expression of the E-cadherin expression was observed by
immunohistochemistry  (IHC)  staining.  Previous  reports
indicated that the nuclear β-catenin associated with TCF/LEF
proteins will activate the target genes, such as cyclin D1 and
c-myc  [19,20,28],  leading  to  cellular  proliferation  and
division [19,20,28,29]. The nuclear β-catenin involved in the
progression of proliferation has been found in several types
of cancers [30]. In pterygia, a previous report has indicated
that the E-cadherin, as well as β-catenin, was heterogeneously
expressed in the cell membrane and cytoplasm of pterygia. In
addition,  β-catenin  immunoreactivity  were  also  showed
intense nuclear in several epithelial cells [31]. The results
were similar with our finding. As shown in Figure 1, we not
only  found  reduced  protein  but  also  aberrant  protein
localization  of  the  β-catenin  protein  in  pterygium.
Additionally,  the  frequency  of  aberrant  localization  of  β-
catenin in the E-cadherin negative groups was significantly
higher than in the positive groups. Therefore, we recognize
that  the  changes  in  E-cadherin  signaling  pathway  protein
expression and localization are involved in pterygium cell
proliferation.
Aberrant  promoter  hypermethylation  of  the  tumor
suppressor  genes  inactivates  the  gene  function,  and  the
resultant  gene  silencing  plays  an  important  role  in  the
pathogenesis of most, if not all, types of human cancer [32].
In  addition,  the  hypermethylation  may  act  to  freeze
inactivated  genes  in  the  “off”  position.  However,  the
mechanisms involved in hypermethylating DNA loci remain
unclear. The global cytosine methylation patterns in mammals
appear to be established by a complex interplay of at least
three  independently  encoded  DNA  methyltransferases
(DNMTs), including DNMT1, DNMT3a and DNMT3b [33,
34].  Our  previous  study  showed  that  29.5%  of  pterygial
specimens tested positive for DNMT3b protein expression
[35]. In the present study, MS-PCR was performed to analyze
promoter hypermethylation of E-cadherin (CDH1). Fifty-one
per cent of the pterygia without E-cadherin protein expression
were associated with promoter hypermethylation. In addition,
13.9% of the pterygia with E-cadherin protein expression
were  associated  with  CDH1  promoter  hypermethylation
(p<0.0001, Table 2). Therefore, decreased expression of E-
cadherin  protein  might  be  related  to  promoter
hypermethylation.
A  previous  report  indicated  that  Snail  and  Slug,
repressors of E-cadherin transcription, inhibit the expression
of  E-cadherin  [36].  The  downstream  cascade,  including
cytoplasmic  accumulation  and  nuclear  translocation  of  β-
catenin, therefore results in epithelial mesenchymal transition
(EMT) and cell proliferation of pterygium epithelial cells.
Although the signaling pathways involving EMT after ligand
activation  are  complex,  the  downregulation  of  E-cadherin
plays a crucial role in pterygial pathogenesis [37]. Previous
reports showed that Histone deacetylation is associated with
transcriptional silencing of E-cadherin in colorectal cancer
and ovarian cell lines [38,39]. Hence, factors, such as gene
mutations,  genomic  deletions,  Histone  deacetylation,  or
polymorphisms causing inactivation of E-cadherin should be
further investigated.
In conclusion, our study is the first to provide evidence
to show that the promoter hypermethylation of E-cadherin
may  be  involved  in  the  reduction  of  E-cadherin  protein
expression  in  pterygium.  Additionally,  we  also  provided
evidence for the detection of aberrant protein localization of
β-catenin  in  pterygium.  These  data  provide  evidence  that
changes in E-cadherin signaling may contribute to pterygium
cell proliferation.
TABLE 2. RELATIONSHIP BETWEEN E-CADHERIN GENE PROMOTER HYPERMETHYLATION AND PROTEIN EXPRESSION IN PTERYGIUM.
    Protein  
E-cadherin Total Negative N (%) Positive N (%) p value
Promoter methylation
Negative 88 20 (22.7) 68 (77.3)  
Positive 32 21 (65.6) 11 (34.4) <0.0001
TABLE 3. RELATIONSHIP OF E-CADHERIN PROTEIN EXPRESSION AND β-CATENIN PROTEIN LOCALIZATION IN PTERYGIUM.
  E-cadherin  
β-catenin Negative (n=41; %) Positive (n=79; %) p value
Negative (n=62) 18 (43.9) 44 (55.7)  
Positive
Membrane (n=33) 3 (7.4) 30 (38.0)  
Nuclei/Cytoplasm 20 (48.7) 5 (6.3) <0.0001
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